# Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB

> **NCT03315182** · PHASE1,PHASE2 · TERMINATED · sponsor: **Abeona Therapeutics, Inc** · enrollment: 11 (actual)

## Conditions studied

- Mucopolysaccharidosis Type 3 B

## Interventions

- **BIOLOGICAL:** rAAV9.CMV.hNAGLU

## Key facts

- **NCT ID:** NCT03315182
- **Lead sponsor:** Abeona Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-16
- **Primary completion:** 2022-04-07
- **Final completion:** 2022-04-07
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Abeona has decided to discontinue development activities for Product ABO-101 due to a lack of drug supply and for business reasons unrelated to the product safety profile and/or signs of efficacy
- **Last updated:** 2022-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03315182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03315182, "Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03315182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*